Nuclear Receptor Subfamily 2 Group F Member 1 — Market Intelligence, Transcription Factor Inhibitor/Agonist Development, and High-Purity Reagents for Oncology (Metastasis, Tumor Dormancy) and Regenerative Medicine Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NR2F1 drug discovery. As an intracellular orphan nuclear receptor, NR2F1 requires specialized biochemical and cell-based validation tools. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NR2F1 Full-Length / LBD / DBD Recombinant Protein HEK293 Expressed, His or GST Tag, High Purity (>95%), Sequence Verified, Endotoxin <1EU/µg |
View NR2F1 Products |
| Gene Delivery | NR2F1 Premade Lentivirus / Promise-ORF Full-length ORF for stable cell line construction and transcriptional assays |
View NR2F1 Products |
| Benchmark Ab | Anti-NR2F1 Rabbit mAb (Clone COUP-TFI-1) Recombinant positive control for Western/IP/ChIP |
View NR2F1 Products |
| Validator | NR2F1 siRNA Set (3 unique targets) For knockdown verification and specificity controls |
View NR2F1 Products |
| Related Target: NR2F2 | COUP-TFII (Nuclear Receptor Subfamily 2 Group F Member 2) Close paralog for selectivity screening and heterodimer studies |
View NR2F2 Products |
| Related Target: RXRA | Retinoid X Receptor Alpha Heterodimeric partner; essential for NR2F1 allosteric network assays |
View RXRA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Access (TFDD) | Cell-Permeable Validation Tools: Lentivirus-based stable expression systems with puromycin selection; Nuclear localization signal (NLS) intact |
| DNA Binding Domain Integrity & Conformational Stability | Full-Length ORF Construct & Rational LBD design: Native conformation preservation for EMSA, SPR, and ITC |
| Paralog Selectivity (NR2F1 vs NR2F2) | Ortholog Panel: Human NR2F1 and NR2F2 proteins available with >95% purity, mass spec verified for binding assays |
| Co-Regulator Recruitment | High-Concentration Stability: Theoretical MW validation for AlphaScreen/TR-FRET assays |
| Lack of Controls & False Positives | Validated siRNA included for specificity checks; Anti-NR2F1 antibody for ChIP/qPCR; Pure proteins for counter-screening |
Live NR2F1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NR2F1 therapeutics represents a paradigm shift in oncology, encompassing two complementary strategies: transcription factor inhibition (targeting overexpressed NR2F1 in metastatic prostate cancer and triple-negative breast cancer) and tumor dormancy activation (using small molecule agonists to induce long-term dormancy in disseminated tumor cells, preventing relapse). As an orphan nuclear receptor (COUP-TFI), NR2F1 has emerged from developmental biology into serious oncology target validation.
In the inhibition strategy, major players are shifting focus from traditional ligand-binding approaches to targeted protein degradation (PROTACs) and allosteric inhibitors, with molecular glues entering preclinical validation for disrupting heterodimer interactions. In the activation strategy, first-generation tool compounds like C26 validate the mechanism of inducing dormancy in head and neck, breast, and prostate cancers, driving the development of potent, highly selective small molecule agonists as adjuvant therapies.
Beyond oncology, NR2F1 loss-of-function mutations cause Bosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS), a rare neurodevelopmental disorder, where gene therapy or modulators are being explored. Key mutations include p.Arg112Cys and p.Leu362Serfs*21 (both decrease transcriptional activity in BBSOAS), and a mutation found in a patient with early infantile epileptic encephalopathy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Academic consortia, Emerging biotechs | Metastatic Prostate Cancer | Cell-based degradation assays (Need full-length NR2F1 Lentivirus for stable lines) |
| Allosteric Inhibitor | Pharma partnerships | Solid Tumors | Protein Stability Shift Assays (Need high-purity LBD protein) |
| Molecular Glue | Biotech discovery platforms | CRPC | Ternary Complex Formation (Need recombinant NR2F1 + co-regulator panels) |
| Small Molecule Agonist | Emerging Biotech / Academic Spin-offs | Solid Tumors (Metastasis Prevention) | Selectivity Assay (Need High-Purity LBD Proteins for SPR) |
| Gene Therapy / Modulators | Preclinical Innovators | BBSOAS (Rare Genetic Disorder) | Expression Validation (Need Lentivirus and Reference Abs) |
| Combination Therapy | Translational Oncology Labs | Chemoresistant Cancers | Pathway Analysis (Need siRNA and Transcriptional Reporters) |
Key Mutations & Disease Associations
Based on curated variant data (UniProt P10589):
- Early Infantile Epileptic Encephalopathy (VAR_078708): A mutation found in a patient with early infantile epileptic encephalopathy, highlighting NR2F1's role in neurodevelopment.
- BBSOAS p.Arg112Cys (VAR_071319, rs587777277): Decreases transcriptional activity; associated with optic atrophy and developmental delay.
- BBSOAS p.Leu362Serfs*21 (VAR_071320, rs587777275): Also decreases transcriptional activity; frameshift mutation causing loss of function. These variants underscore the importance of functional assays (luciferase reporters, ChIP) for evaluating potential therapeutics in both oncology and rare disease contexts.